Villere ST Denis J & Co. LLC Buys 345,820 Shares of Pfizer Inc. $PFE

Villere ST Denis J & Co. LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 218.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 504,355 shares of the biopharmaceutical company’s stock after acquiring an additional 345,820 shares during the period. Villere ST Denis J & Co. LLC’s holdings in Pfizer were worth $12,558,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of PFE. Y Intercept Hong Kong Ltd purchased a new position in Pfizer in the third quarter worth about $3,019,000. Money Concepts Capital Corp raised its holdings in shares of Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after purchasing an additional 57,188 shares during the last quarter. Vista Investment Partners LLC raised its holdings in shares of Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after purchasing an additional 48,900 shares during the last quarter. Kepler Cheuvreux Suisse SA purchased a new position in shares of Pfizer during the third quarter valued at approximately $16,613,000. Finally, Fort Washington Investment Advisors Inc. OH raised its holdings in shares of Pfizer by 11.2% during the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,892,663 shares of the biopharmaceutical company’s stock valued at $48,225,000 after purchasing an additional 190,946 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Royal Bank Of Canada reissued an “underperform” rating and set a $25.00 price objective on shares of Pfizer in a report on Monday. TD Cowen restated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. UBS Group boosted their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research report on Monday, April 13th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research report on Monday, March 2nd. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $28.48.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Board declared a $0.43 Q2 2026 dividend (payable June 12; record May 8) — the 350th consecutive quarterly dividend, supporting income-focused investors and signaling cash-flow confidence. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: FDA granted Priority Review for PADCEV + Keytruda in muscle‑invasive bladder cancer — approval would expand a high‑value oncology indication and materially improve Pfizer’s oncology revenue mix if approved. PADCEV Priority Review
• Positive Sentiment: Company to present extensive oncology data at ASCO (multiple late‑breaking and oral presentations) — positive readthroughs could improve growth expectations for Pfizer’s cancer pipeline. Pfizer ASCO Presentations
• Positive Sentiment: Pfizer’s GLP‑1 weight‑management drug is available for pre‑order in China — early commercial activity in a large obesity market could add a new growth stream. GLP-1 Pre-order in China
• Neutral Sentiment: Analysts and commentary highlight Pfizer’s cost cuts and recurring earnings‑beat track record, suggesting upside risk into the next report but leaving forecasts mixed. Earnings Preview
• Neutral Sentiment: Market reports list Pfizer among key players in the growing drug‑delivery devices market — strategic relevance but not an immediate revenue catalyst. Drug Delivery Devices Market
• Negative Sentiment: Royal Bank of Canada assigned an Underperform rating — analyst downgrades can pressure shares and reduce near‑term investor appetite. RBC Underperform Rating
• Negative Sentiment: Top strategy executive departing — leadership turnover can spark uncertainty about execution of strategic initiatives. Strategy Executive Leaving
• Negative Sentiment: Shares slid while broader markets gained, suggesting sector rotation, profit‑taking after recent gains, or reaction to the analyst/exec items described above. Stock Sinks As Market Gains

Pfizer Stock Performance

Shares of NYSE PFE opened at $26.78 on Thursday. The firm has a 50 day moving average of $27.26 and a 200 day moving average of $26.05. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $152.28 billion, a price-to-earnings ratio of 19.69 and a beta of 0.43. Pfizer Inc. has a 12-month low of $21.97 and a 12-month high of $28.75.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.63 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio is presently 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.